ALBANY, New York, June 11, 2015 /PRNewswire/ --
According to a new market report published by Transparency Market Research Pipeline Review of Glioblastoma Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2022, the global glioblastoma treatment market was valued at USD 0.34 billion in 2013 and is estimated to reach USD 0.91 billion by 2022 at a CAGR of 11.4% from 2014 to 2022.
To browse through the ToC or purchase the Glioblastoma Treatment Market Report, please visit: http://www.transparencymarketresearch.com/pipeline-review-of-glioblastoma-treatment-market.html
Glioblastoma multiforme (GBM), also categorized as high-grade glioma, is the most aggressive astrocytic tumor, composed of poorly differentiated neoplastic astrocytes (subtype of central nervous system cells). The pipeline analysis of the GBM treatment market has been segmented on the basis of type of drug and geography. Three drugs that cover the major market of GBM treatment are bevacizumab (Avastin), temozolomide (Temodar/Temodal/Temcad), and carmustine (BiCNU). Regions covered in the geography segment include North America, Europe, Asia Pacific, and Rest of the World (RoW).
For additional information about the Glioblastoma Treatment Market Report, visit: http://www.transparencymarketresearch.com/sample/sample.php?flag=s&rep_id=4807
The FDA approved treatments for GBM comprises carmustine, temozolomide, and bevacozumab. Carmiustine drug is brand named as Gliadel (Arbor Pharmaceuticals, LLC) which is a surgical implant, while bevacozumab (Brand name Avastin, product of Genetech/Roche) is targeted for intravenous therapy and temozolomide (Temodar/Temodal/Temcad and other brands) is recommended for intravenous or oral chemotherapy. The factors driving the glioblastoma treatment market include rising awareness against various types of brain tumors, research and development in drug delivery technologies and combination of modern diagnostic techniques. In 2013, temozolomide dominated the global glioblastoma market due to the therapeutic benefit of alkylated/methylated DNA, which most often occurs at the N-7 or O-6 positions of guanine residues. In 2012, the drug had lost its exclusivity and lead to the entry of generic drugs in the market, thereby, reducing the market share globally.
Get full Press Release of Glioblastoma Treatment Market Report, here: http://www.transparencymarketresearch.com/pressrelease/pipeline-review-of-glioblastoma-treatment-market.htm
Geographically, in 2013 North America dominated the global glioblastoma market owing to rising incidences of glioblastoma multiforme (GBM) coupled with increasing number of associations such as American Brain Tumor Association, National Brain Tumor Society, Brain Tumor Foundation of Canada and others engaged in raising awareness for GBM in the region. In addition, majority of the manufacturers developing drugs for the treatment of glioblastoma are domiciled in the region thereby, supporting the dominance of the North America market. Asia Pacific is the most lucrative regional market for glioblastoma due to rising awareness against GBM which is boosting the diagnostic rate in Asia Pacific and developing healthcare infrastructure by upgrading the diagnostic and treatment facilities in Asia Pacific.
Other Press Releases of Glioblastoma Treatment Market:
- North America Dominated the Global Glioblastoma Treatment Market. The Global Glioblastoma Treatment Market Expected to Reach USD 0.91 Billion in 2022 http://www.transparencymarketresearch.com/pressrelease/glioblastoma-treatment-industry.htm
- Increasing Incidences of Glioblastoma Multiforme Propels the Growth of Global Glioblastoma Treatment Market, Expected to Reach USD 0.91 Billion in 2022 http://www.transparencymarketresearch.com/pressrelease/global-glioblastoma-treatment-market.htm
- Pipeline Review of Glioblastoma Treatment Market Expected to Reach USD 0.91 Billion in 2022 http://www.transparencymarketresearch.com/pressrelease/global-glioblastoma-treatment-industry.htm
Merck & Co., Inc., F. Hoffmann-Le Roche AG, and Arbor Pharmaceuticals, LLC are the key players dominated the global GBM treatment market in 2013. The other generic drug manufacturers present in the global glioblastoma market are Teva Pharmaceutical Industries, Ltd., Amneal Pharmaceuticals. LLC, Sun Pharmaceutical Industries, Ltd., amongst others.
The pipeline review of glioblastoma treatment market has been segmented as below:
- Global Glioblastoma Treatment Market Revenue and Forecast, by Drugs
- Bevacizumab (Avastin)
- Temozolomide (Temodar and Temodal and Temcad)
- Carmustine (BiCNU)
- Global Glioblastoma Treatment Market Revenue and Forecast, by Geography
- North America
- Asia Pacific
- Rest of the World
- Global Pipeline Review of Glioblastoma Treatment
- Late Stage (Phase III)
- Rindopepimut (CDX-110)
- Early Stage (Phase I, II and Pre clinical)
Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Mr. Nachiket Ghumare
90 State Street, Suite 700
Albany, NY 12207
USA - Canada Toll Free: 866-552-3453
SOURCE Transparency Market Research